JAZZ News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

JA

Mkt Cap

$13.65B

Volume

504.75K

Next Earnings

November 4th

Loading chart

JA

JAZZJazz Pharmaceuticals, Inc.

JAZZ

Pay with—

Available Balance0.00

JA

Mkt Cap

$13.92B

Volume

504.75K

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

HRMY Stock Gains 27.6% in Six Months: Is There More Room for Growth?Harmony Biosciences (HRMY) has outperformed the market with a 27.6% share surge over six months, driven by robust Wakix sales growth of 24% to $476.7 million in H1 2026 and promising pipeline candidates BP-205 and EPX-100. The company maintains its $1.0-$1.04B full-year revenue guidance and has $962.5M in cash to fund development. However, competition from Jazz Pharmaceuticals' Xywav and Alkermes' Lumryz, along with patent litigation risks, present headwinds.Zacks Investment Research · Oct 16, 2026

Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value StockZacks Premium offers investment research tools including the Zacks Rank and Style Scores to help investors identify stocks with strong performance potential. The Zacks Rank #1 stocks have averaged +23.86% annual returns since 1988, more than double the S&P 500. Style Scores (Value, Growth, Momentum, and VGM) help narrow down top-rated stocks by evaluating their characteristics. Jazz Pharmaceuticals is highlighted as a stock to watch with a #3 Hold rank and VGM Score of A.Zacks Investment Research · Oct 6, 2026

Should You Buy Jazz Pharmaceuticals Stock After Its Actio Acquisition?Jazz Pharmaceuticals acquired Actio Biosciences for $820 million upfront plus up to $500 million in milestone payments to gain control of ABS-1230, a potential first-in-class treatment for KCNT1-related epilepsy. The acquisition strengthens Jazz's existing epilepsy franchise, which includes the successful Epidiolex drug generating $292 million in Q2 sales. While clinical trial risks exist, Jazz's strong revenue growth (16% YoY to $1.2 billion in Q2) and solid cash generation support the investment. At 9.5x forward earnings, the stock appears reasonably valued for a profitable biotech with double-digit growth.The Motley Fool · Sep 18, 2026

Why Is Jazz (JAZZ) Down 6.9% Since Last Earnings Report?Jazz Pharmaceuticals missed Q2 2026 EPS expectations ($5.71 vs. $6.04 estimate) due to $77 million in acquired IPR&D expenses, but beat revenue estimates at $1.21 billion. The company raised full-year 2026 revenue guidance to $4.60-$4.75 billion, driven by strong performance in its sleep franchise (Xywav up 13%), epilepsy business (Epidiolex up 16%), and oncology portfolio (up 32%). Despite the positive outlook, shares have underperformed the S&P 500 by 6.9% since the earnings report.Zacks Investment Research · Sep 2, 2026

Axsome Begins Phase III Study on AXS-05 for Smoking CessationAxsome Therapeutics has dosed the first patient in the phase III SUMMIT study evaluating AXS-05 for smoking cessation. The randomized, double-blind, placebo-controlled trial will compare AXS-05 against bupropion and placebo over 12 weeks, with smoking abstinence as the primary endpoint. Axsome's lead drug Auvelity continues to drive strong revenue growth, generating $333 million in H1 2026 (up 54.2% YoY), while the company's diversified portfolio includes Sunosi and newly launched Symbravo.Zacks Investment Research · Sep 1, 2026

JAZZ Rises on Updated OS Results From Gastric Cancer StudyJazz Pharmaceuticals announced second interim results from the HERIZON-GEA-01 study showing statistically significant overall survival improvements for Ziihera plus chemotherapy versus standard of care trastuzumab plus chemotherapy in HER2-positive gastroesophageal adenocarcinoma. The three-drug regimen of Ziihera plus Tevimbra and chemotherapy also demonstrated improved OS hazard ratios with longer follow-up. These results support the recent FDA label expansion of Ziihera for first-line treatment in this indication, significantly expanding its commercial opportunity.Zacks Investment Research · Sep 1, 2026

Zymeworks Announces Participation in Upcoming Investor ConferencesZymeworks Inc. announced its participation in three upcoming investor conferences: the 2026 Stifel Virtual Targeted Oncology Forum (May 20), TD Cowen 7th Annual Oncology Innovation Summit (May 27), and 2026 Jefferies Global Healthcare Conference (June 3). The company will engage in fireside chats and one-on-one meetings to discuss its portfolio of licensed healthcare assets and pipeline of novel biotherapeutics.GlobeNewswire Inc. · May 13, 2026

Pheochromocytoma and Paraganglioma Market to Exhibit Growth at 7.3% CAGR by 2036 Driven by the Advent of Drug Classes Such as SSTR2 analogs, Dopamine Receptor D2 Agonists, TAAs or TSAs, and Others | DelveInsightThe pheochromocytoma and paraganglioma (PCPG) market is projected to grow at 7.3% CAGR through 2036, driven by emerging therapies including radioligand treatments, HIF-2α inhibitors, and targeted agents. The market was valued at USD 300 million in 2025 across seven major markets, with the US accounting for 67% of the market. Key companies including Novartis, Jazz Pharmaceuticals, Perspective Therapeutics, and Merck are advancing innovative treatments, with WELIREG (belzutifan) expected to generate the highest revenue by 2036.GlobeNewswire Inc. · Apr 20, 2026

Artios Strengthens Leadership Team to Accelerate Late-Stage Development of Potential First-in-Class Oncology PipelineArtios Pharma appointed three senior leaders to strengthen late-stage development capabilities: Roy W. Ware as Chief Manufacturing and Technology Officer, Caryn Barnett as VP of Clinical Operations, and Pablo Lee as VP of Medical Affairs. These appointments aim to accelerate the company's DDR-based oncology pipeline, particularly alnodesertib, toward potential commercialization and FDA approval.GlobeNewswire Inc. · Feb 16, 2026

Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026Zymeworks Inc. announced it will report its fourth quarter and full year 2025 financial results on March 2, 2026, followed by a conference call at 8:30 am ET. The biotechnology company is managing a portfolio of licensed healthcare assets and developing multifunctional biotherapeutics, with key products including Ziihera and partnerships with BeOne Medicines and Jazz Pharmaceuticals for commercialization rights.GlobeNewswire Inc. · Feb 12, 2026

to start trading

JA

JAZZJazz Pharmaceuticals, Inc.

JAZZ

Pay with—

Available Balance0.00

Your PositionYou don't own any JAZZ yet.

Related Tickers

Earnings